Ardelyx, Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and commercializes small molecule therapeutics that work in the gastrointestinal tract to treat cardio-renal, GI and metabolic diseases. The Company's lead product candidate is Tenapanor which is in three ongoing Phase II clinical trials for the treatment of patients with ESRD-HD and chronic kidney disease, as well as for constipation-predominant irritable bowel syndrome. Ardelyx, Inc. is headquartered in Fremont, California.
| Revenue (Most Recent Fiscal Year) | $333.61M |
| Net Income (Most Recent Fiscal Year) | $-39.14M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 3.73 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 10.31 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -14.36% |
| Net Margin (Trailing 12 Months) | -14.60% |
| Return on Equity (Trailing 12 Months) | -36.57% |
| Return on Assets (Trailing 12 Months) | -13.42% |
| Current Ratio (Most Recent Fiscal Quarter) | 4.30 |
| Quick Ratio (Most Recent Fiscal Quarter) | 4.03 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 1.44 |
| Inventory Turnover (Trailing 12 Months) | 2.99 |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.73 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.08 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.17 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.23 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 240.98M |
| Free Float | 229.42M |
| Market Capitalization | $1.44B |
| Average Volume (Last 20 Days) | 4.44M |
| Beta (Past 60 Months) | 0.68 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.80% |
| Percentage Held By Institutions (Latest 13F Reports) | 58.92% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |